Current status of human papillomavirus vaccination implementation in central and eastern Europe.

We present a review of the current implementation status of vaccination against human papillomaviruses (HPV) and available data concerning the burden of HPV infection and HPV type-specific distribution in 16 central and eastern European countries: Albania, Bosnia and Herzegovina, Bulgaria, Croatia, the Czech Republic, Estonia, Montenegro, Poland, Romania, Serbia, Slovakia, Slovenia, and The Former Yugoslav Republic of Macedonia. At least one current HPV prophylactic vaccine is registered in all central and eastern European countries except Montenegro. Six counties-Bulgaria, the Czech Republic, Latvia, Romania, Slovenia, and Former Yugoslav Republic of Macedonia-have integrated the HPV vaccination into their national immunization program and currently provide routine vaccination free of charge to the primary target population. Ten countries have not integrated HPV vaccination into the national immunization program. The key reasons for lack of implementation of HPV vaccination into the national immunization program are the high vaccine cost and negative public perception. Vaccination of males is not recommended in any country in the region.

[1]  M. Poljak,et al.  Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe. , 2013, Vaccine.

[2]  H. Cubie,et al.  Human papillomavirus vaccine introduction--the first five years. , 2012, Vaccine.

[3]  Z. Kaló,et al.  Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary , 2012, BMC Public Health.

[4]  P. Lopalco,et al.  The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey. , 2010, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[5]  A. Mrhar,et al.  Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia. , 2010, European journal of public health.

[6]  E. Dasbach,et al.  The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary , 2010, Journal of medical economics.

[7]  B Romanowski,et al.  Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women , 2009, The Lancet.

[8]  V. Usonis,et al.  Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for the introduction of HPV vaccines , 2009, European Journal of Pediatrics.

[9]  E. Dasbach,et al.  The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan. , 2008, Asian Pacific journal of cancer prevention : APJCP.

[10]  Henry C Kitchener,et al.  Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial , 2007, The Lancet.

[11]  F. X. Bosch,et al.  Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions , 2007 .

[12]  G. Krogh,et al.  High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up , 2006, British Journal of Cancer.

[13]  G. Sanders,et al.  Evaluating Human Papillomavirus Vaccination Programs , 2004, Emerging infectious diseases.

[14]  Human papillomavirus and cervical cancer. Summary report. , 1989, IARC scientific publications.